-Lung endothelial cells respond to changes in vascular pressure through mechanotransduction pathways that alter barrier function via non-Starling mechanism(s). Components of the endothelial glycocalyx have been shown to participate in mechanotransduction in vitro and in systemic vessels, but the glycocalyx's role in mechanosensing and pulmonary barrier function has not been characterized. Mechanotransduction pathways may represent novel targets for therapeutic intervention during states of elevated pulmonary pressure such as acute heart failure, fluid overload, and mechanical ventilation. Our objective was to assess the effects of increasing vascular pressure on whole lung filtration coefficient (Kfc) and characterize the role of endothelial heparan sulfates in mediating mechanotransduction and associated increases in Kfc. Isolated perfused rat lung preparation was used to measure Kfc in response to changes in vascular pressure in combination with superimposed changes in airway pressure. The roles of heparan sulfates, nitric oxide, and reactive oxygen species were investigated. Increases in capillary pressure altered Kfc in a nonlinear relationship, suggesting non-Starling mechanism(s). nitro-L-arginine methyl ester and heparanase III attenuated the effects of increased capillary pressure on Kfc, demonstrating active mechanotransduction leading to barrier dysfunction. The nitric oxide (NO) donor S-nitrosoglutathione exacerbated pressure-mediated increase in Kfc. Ventilation strategies altered lung NO concentration and the Kfc response to increases in vascular pressure. This is the first study to demonstrate a role for the glycocalyx in whole lung mechanotransduction and has important implications in understanding the regulation of vascular permeability in the context of vascular pressure, fluid status, and ventilation strategies. endothelium; pulmonary edema; permeability THE ENDOTHELIAL GLYCOCALYX has been hypothesized to play a role in vascular barrier regulation through both passive and active mechanisms. Passive properties include the formation of a molecular filter overlying the cell-cell junction that limits water flux (2, 14) and protein flux (3, 38, 41) into the cell junction. Active barrier regulation occurs through mechanotransduction that alters junctional integrity via nitric oxide (NO) and reactive oxygen species (ROS) (15, 16, 18) . Observations regarding glycocalyx-mediated signal transduction, however, have come from cultured endothelial cells and not from in vivo or ex vivo whole organ studies that would validate a physiological role for the glycocalyx in a more complex as well as clinically relevant model.
THE ENDOTHELIAL GLYCOCALYX has been hypothesized to play a role in vascular barrier regulation through both passive and active mechanisms. Passive properties include the formation of a molecular filter overlying the cell-cell junction that limits water flux (2, 14) and protein flux (3, 38, 41) into the cell junction. Active barrier regulation occurs through mechanotransduction that alters junctional integrity via nitric oxide (NO) and reactive oxygen species (ROS) (15, 16, 18) . Observations regarding glycocalyx-mediated signal transduction, however, have come from cultured endothelial cells and not from in vivo or ex vivo whole organ studies that would validate a physiological role for the glycocalyx in a more complex as well as clinically relevant model.
Recently, we reported that lung capillary endothelial cells, in vitro, respond to increases in hydrostatic pressure by production of intracellular NO and ROS that mediate barrier dysfunction manifested by an increase in hydraulic conductivity (15, 16, 18) . Pressure-induced production of NO is a response characteristic of whole lung microvessels (24) , clearly demonstrating that cultured endothelial cells and in situ pulmonary vessels share common responses to hemodynamic forces. We demonstrated that heparan sulfates (HS) were crucial for both the activation of endothelial nitric oxide synthase (eNOS) and pressure-induced increase in permeability. The present study extends our observations from cell culture models (15, 16, 18, 24) to a physiologically and clinically relevant model; our results provide the first evidence for a role of the glycocalyx, specifically HS, in mechanotransduction and barrier regulation in the intact lung.
METHODS

Ex Vivo Lung Preparation
All animal experiments were approved by the University of Utah's Institutional Animal Care and Use Committee and in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council).
Adult male Sprague-Dawley rats (300 -400 g) were anesthetized with ketamine-xylazine (90:10 mg/kg), a tracheotomy was performed and they were mechanically ventilated with a pressure-controlled ventilator (Kent Scientific, Torrington, CT) at a respiratory rate of 60/min, FI O 2 ϭ 0.21 and positive end-expiratory pressure (PEEP) of 3.0 cmH 2O. The chest and pericardial sac were sequentially opened and ligatures were placed around the aorta and pulmonary artery. Heparin (200 U) was injected into the pulmonary artery and allowed to circulate for 2 min. The rat was exsanguinated via transection of the abdominal aorta; the left atrium was cannulated via a left ventriculostomy. The pulmonary artery was cannulated via the right ventricle and lungs were perfused with Krebs-Ringer-bicarbonate solution containing 3% bovine serum albumin.
Pulmonary arterial (Ppa) and left atrial pressures (P LA) were measured continuously via in-line pressure transducers (P-75, Harvard Apparatus, Natick, MA) connected to an analog-to-digital board. Solenoids (20 PSI, 12 V DC, Cole Parmer; Mount Vernon, IL) were placed in-line on both the arterial and venous tubing and could be closed simultaneously for measuring double-occlusion pressures (Pdo). An in-line ultrasonic flow probe (Transonic, Ithaca, NY) was placed in the pulmonary artery cannula and flow data was recorded in real time. Lungs were suspended from a force transducer (Radnoti, Monrovia, CA) and lung weight was zeroed; lung weight, vascular pressures and flow were recorded using a custom-written program (LabVIEW, National Instruments, Austin, TX).
Reagents
Heparanase III (E.C. 4.2.2.8) was from Ibex Technologies (Montreal, QC, Canada); Krebs-Ringer buffer, nitro-L-arginine methyl ester (L-NAME), nitro-D-arginine methyl ester (D-NAME), S-nitrosoglutathione (GSNO), and diethyl pyrocarbonate (DEPC) were purchased from Sigma Chemical (St. Louis, MO); Mn(III)-tetra(4-benzoic acid) porphyrin chloride (TBAP) was purchased from Biomol (Plymouth Meeting, PA). Bovine serum albumin fraction V was purchased from Proliant (Ankeny, IA). Anti-nitrotyrosine was from Abcam (Cambridge, MA) and HSS-1 and 3G10 from US Biological (Swampscott, MA).
Calculation of K fc
The change in lung weight expressed as milliliters of filtered fluid during the time interval from 18 to 20 min was divided by time (2 min) and then by the capillary pressure (Ppc), where Ppc ϭ (Ppa ϩ Pla)/2, yielding milliliters per minute per centimeter H 2O (32) ; this value was normalized to 100 g of predicted lung weight (PLW), which was calculated from the equation PLW ϭ 0.0053 (rat weight) Ϫ 0.48 (32) .
Pressure-Volume Curves
Tidal volumes (VT) in isolated perfused rat lungs during pressurecontrolled ventilation were measured with a differential pressure transducer (DP-45, Validyne, Northridge, CA), driven by a Carrier Frequency Bridge Amplifier (type 677, Hugo Sachs Elektronik-Harvard Apparatus). Airflow (ml/s) was recorded with a custom-written program (LabVIEW 8.5, National Instruments, Austin, TX) at 200 Hz sampling rate, and each respiratory cycle was integrated to obtain VT. A calibration curve was created by applying gas flow (air) (air pressure ϭ 1 bar) from negative 16.16 ml/s (vacuum) to positive flow at 16.16 ml/s, through the DP-45 and recording the corresponding voltage output. This flow was regulated with a calibrated flowmeter (Dwyer, model UA1049) (accuracy Ϯ2%) connected to a pressure regulator. The calibration curve was entered in a custom scale before recording of VT. The lungs were ventilated with different peak inspiratory pressures (PIPs) and positive end-expiratory pressures (PEEPs) (⌬P ϭ PIPϪPEEP) to record the resulting VT values. Flow/VT was recorded for 1 min for each ⌬P. We used inflation pressures that produced VTs identical to previous literature values (20, 33) during standard tidal volume (ST VT). Low tidal volume ventilation (Low VT) inflation pressures were chosen to recreate clinically relevant lung-protective strategies.
TISSUE NITRATE/NITRITE CONCENTRATIONS
Whole-lung protein preparations were assayed in triplicate for concentrations of nitrate/nitrite (NO x ) using a chemiluminescence analyzer for NO detection (NOA 280i; Sievers Instruments, Boulder, CO) as previously described (27) . Briefly, 50 l of sample was injected into the reaction chamber containing a saturated solution of 0.05 M vanadium (III) chloride in 1 M HCl heated to 95°C to reduce NO x to NO. The liberated NO was carried in gas phase into the analyzer by a constant flow of helium gas. The analyzer was calibrated by using a standard curve derived from serial dilutions of a 0.1 M stock solution of sodium nitrite (NaNO 2 ). Individual results for tissue NO x are expressed as micromoles of NO per micrograms total protein per ⌬ wet weight; the normalization to ⌬ wet weight is to correct for the dilution of NO x by increased extravascular lung water.
Immunohistochemistry
Lungs were perfused with neutral-buffered formalin via the pulmonary artery while Pla was held at 5 cmH 2 O; formalin was also instilled into the trachea at a pressure of 25 cmH 2 O. Lungs were processed by standard histological methods. Anti-NOtyrosine, HSS-1, and 3G10 antibodies were conjugated to a biotin-labeled secondary antibody (IgM) and then incubated with streptavidin-horseradish peroxidase.
Experimental Protocols
Protocol 1: Low VT ϩ double pressure step. Lungs were ventilated at Low VT and perfused for 20 min at isogravimetric pressure. Baseline K fc (K fc1 ) was determined by increasing left atrial pressure (Pla 1 ) to 7.5 cmH 2 O for 20 min followed by a return to isogravimetric conditions for 20 min. A second pressure step (Pla 2 ) to 7.5, 10, 12, and 15 cmH 2 O was performed for 20 min and K fc2 was measured. The ratio K fc2 /K fc1 was used to assess the influence of Pla on the filtration coefficient. Double-occlusion pressures (Pdo 1 , Pdo 2 , Pdo 3 ) were measured before and after each pressure step to ensure stability of the individual preparation. The general scheme for the double-step protocol is shown in Fig. 1A , top and middle.
The double pressure step protocol was used for the following groups: control, L-NAME, TBAP, heparanase III, and GSNO. Test reagents were infused into pulmonary artery beginning 10 min into the second isogravimetric period and were present in the recirculating media for the remainder of the experiment. Test reagents were used at the following concentrations: L-NAME (200 M), TBAP (200 M), heparanase III (75 and 150 mIU/ml), and GSNO (500 M).
Protocol 2: ST VT ϩ double pressure step protocol. Lungs were ventilated with ST VT, and K fc was measured at baseline Pla ϭ 7.5 cmH 2 O and after a second step of Pla to 15 or 17 cmH 2 O, as described above. Reagents were added to the perfusate beginning 10 min into isogravimetric period 2 and were present in the circulating media for the remainder of the experiment.
Protocol 3: low VT ϩ single-step protocols. To examine the influence of the baseline K fc measurement (initial pressure pulse) on subsequent K fc measurements, we evaluated K fc following a step from isogravimetric conditions to Pla ϭ 7.5 or 15 cmH 2 O. Pdo values were measured before and after each pressure step. The K fc obtained from ⌬Pla ϭ 0 to 15 cmH 2 O was compared with K fc2 obtained from the double pressure step protocol when Pla ϭ 15 cmH 2 O. L-NAME (final concentration, 200 M) was added to the media 10 min into the isogravimetric period and was present for the step increase in Pla to either 7.5 or 15 cmH 2 O. The general scheme for the single-step protocol is shown in Fig. 1A , bottom.
Statistics
All data are presented as box plots showing sample minimum and maximum, 25th and 75th percentile, and median. Differences between groups were assessed by ANOVA followed by either Tukey's honestly significant difference or Scheffé's post hoc test.
All statistical analyses were performed with Kaleidagraph for Windows (version 4.0.3), Synergy Software (Reading, PA); probability levels (P Ͻ 0.05) were taken to indicate statistical significance. Baseline Kfc1 was determined during step 1 at Pla, 7.5 cmH2O in protocols 1 and 2. During step 2, Pla2 was increased to 7.5, 10, 12, 15, or 17 cmH2O and Kfc2 was measured. The ratio of Kfc2/Kfc1 was used to assess the effect of increasing Pla on whole lung permeability. In protocol 3, lungs were exposed to a single increase in Pla from IG1 to Pla ϭ 7.5 or 15 cmH2O. B: pressure-volume curves. Lungs were ventilated with either Low peak inspiratory pressure (PIP) [7-8 cmH2O , positive endexpiratory pressure (PEEP) ϭ 3 cmH2O] or ST PIP (10 -12 cmH2O, PEEP ϭ 3 cmH2O); airflow vs. time was integrated to derive VT, which was normalized to rat body weight (kg). Pair, air pressure.
RESULTS
Pulmonary Hemodynamics
We assessed pulmonary hemodynamics in all lungs ( 
Lung Pressure-Volume Measurements
Pressure-controlled ventilation was used in the present experimental protocols; to quantify VT delivered at net inflation pressure, we built a custom-made system to integrated airflow per unit time to derive VT. The resulting pressure-VT curve presents ⌬P (PIPϪPEEP) vs. VT, normalized to body weight (kg) (Fig. 1B) . In our Low VT group, average VTs were in the range of 2.0 -2.5 ml/breath; in the ST VT group, VT were 3.0 -3.5 ml/breath. The Low VT group was ventilated with 7-8 cmH 2 O providing a VT per body weight of ϳ4 -6 ml/kg. The ST VT groups were ventilated with 10 -12 cmH 2 O yielding VT per body weight of ϳ6 -8 ml/kg.
Low VT Studies
Baseline K fc . All lungs in the double-step groups had a baseline measurement (K fc1 ) at Pla 1 ϭ 7.5 cmH 2 O; thus K fc1 for all groups was pooled and yielded an average K fc1 ϭ 0.081 Ϯ 0.04 ml·min Ϫ1 ·cmH 2 O Ϫ1 per 100 g (n ϭ 112). Subgroup analysis of baseline K fc1 was compared between all control groups and no differences were noted. This rules out time-and technique-dependent factors that may have confounded subsequent K fc comparisons. Pulmonary artery pressure (Ppa 1 ), double-occlusion pressure (Pdo 1 ), and capillary pressure (Ppc 1 ) are denoted by a subscript "1" to indicate the baseline pressure step from which the measurement was derived.
Protocol 1: double pressure step. The second step increase in Pla is designated Pla 2 , and the measured K fc is denoted as K fc2 . Pulmonary artery pressure (Ppa 2 ), double-occlusion pressure (Pdo 2 ), and capillary pressure (Ppc 2 ) are denoted by a subscript "2" to indicate the second pressure step from which the measurement was derived. The ratio of K fc2 /K fc1 derived when Pla ϭ 7.5 cmH 2 O for both pressure steps (C7-7) is considered "control" for the remainder of the studies. The control K fc2 /K fc1 ϭ 1.43 Ϯ 0.78 (n ϭ 8).
To characterize the influence of increased capillary pressure on K fc , lungs were exposed to a second step increase in Pla 2 Fig. 2A and shows nonlinear dynamics of the pressure vs. permeability relationship that cannot be explained by a simple Starling mechanism.
L-NAME. Inhibition of endothelial NO synthase with L-NAME (200 M) had no effect on pulmonary hemodynamics (Table 1) or on baseline K fc2 /K fc1 (i.e., when Pla 2 ϭ 7.5 cmH 2 O) where L-NAME-treated lungs had a K fc ratio of 1.68 Ϯ 1.35 ml·min Ϫ1 ·cmH 2 O Ϫ1 per 100 g. L-NAME attenuated the in- Table 1 . Rat lung pulmonary hemodynamics
Low Peak Inspiratory Pressure Values are means Ϯ SD; N is sample size. Subscripts l and 2 denote first or second pressure step, respectively, from which the value is derived. Pla, left atrial pressure; Ppa, pulmonary artery pressure; Pc, pulmonary capillary pressure; Pdo, double occlusion pressure. All pressures were measured in cmH2O. crease in K fc2 when Pla 2 ϭ 15 and 17 cmH 2 O (Fig. 2B) . The K fc2 /K fc1 ratio at Pla 2 ϭ 15 cmH 2 O was 3.49 Ϯ 1.40; when Pla ϭ 17 cmH 2 O, K fc2 /K fc1 was 3.70ϩ0.88. These values are significantly different than untreated control (P Ͻ 0.05) as shown in Figs. 2 and 3 . D-NAME (200 M), the inactive enantiomer of L-NAME, had no effect on pressure-induced increase in K fc2 (data not shown). GSNO increased the mean K fc2 /K fc1 ratio when Pla ϭ 15 cmH 2 O to 9.1 (P Ͻ 0.0001) (Fig. 3) .
HEPARANASE III. We tested two concentrations of heparanase III on pressure-mediated increases in K fc . Heparanase III at 75 mIU/ml had no effect on K fc relative to controls (data not shown). At a concentration of 150 mIU/ml, heparanase III had no effect on K fc2 when Pla ϭ 7.5 cmH 2 O, indicating that the enzyme did not alter baseline permeability, but heparanase III significantly attenuated the increase in K fc2 when Pla 2 was increased to 15 cmH 2 O (Hep7-15; Fig. 3 ). Heparanase III significantly reduced K fc2 at Pla 2 ϭ 15 cmH 2 O to 0.134 Ϯ 0.065 vs. 0.65 Ϯ 0.36 in untreated lungs; the K fc2 /K fc1 ratio for heparanase III-treated lung was 3.10 Ϯ 1.59 vs. 7.91 Ϯ 3.28 in untreated lungs (n ϭ 8, P Ͻ 0.0001).
TBAP. The intracellular superoxide dismutase mimetic, TBAP (200 M), had no effect on pressure-induced increase in K fc ratio when assessed at Pla ϭ 15 cmH 2 O. TBAP at 200 M is a high concentration and the duration of exposure was appropriate based on similar uses (25, 30) . K fc2 after a step to Pla 2 ϭ 15 cmH 2 O in TBAP-treated lungs was 0.63 Ϯ 0.19 vs. control K fc2 ϭ 0.65 Ϯ 0.36 ml·min Ϫ1 ·cmH 2 O Ϫ1 per 100 g; K fc2 /K fc1 ϭ 6.74 Ϯ 1.58 was not significantly different than untreated lungs at Pla 2 ϭ 15 cmH 2 O (n ϭ 9; p Ͼ 0.05) (Fig. 3) .
ZONAL CHARACTERISTICS. K fc measurements are dependent on vascular surface area that can be increased by vascular recruitment; zonal characteristics (ZCs) were derived from ⌬Ppa/ ⌬Pla as described by Brower et al. (10, 11) and Anglade et al. (7) and indicate the percentage of zone 2 and 3 conditions at each Pla. In control lungs, ZC significantly increased with the increase in Pla from 7.5 to 10 cmH 2 O (0.44 vs. 0.58; P Ͻ 0.05); additional increases in Pla above 12 cmH 2 O did not result in statistically significant changes in ZC (Fig. 4A) .
ZCs were derived for L-NAME-treated groups at Pla 2 at 7.5, 10, 12, 15, and 17 cmH 2 O (Fig. 4A) ; increases in Pla from 7.5 to 10 cmH 2 O resulted in the only statistical difference in ZC. A comparison of ZC for control, heparanase III-treated, and L-NAME-treated lung at Pla 2 ϭ 15 cmH 2 O is shown in Fig. 4B . There were no significant differences in ZC between treatment groups at Pla ϭ 15 cmH 2 O, suggesting that recruitment was not responsible for observed differences in K fc when Pla 2 ϭ 15 cmH 2 O with heparanase and L-NAME.
INTERSTITIAL VOLUME. To assess the effect of increased Pla 2 and treatments (heparanase, L-NAME) on interstitial volume, we measured the retained lung weight after the second pressure steps (⌬VI) and normalized this value to predicted lung weight (PLW). A plot of ⌬VI/PLW for each group demonstrates that heparanase III and L-NAME significantly reduced interstitial volume, in direct correlation with their effects the K fc2 /K fc1 ratio (Fig. 5) .
Protocol 2: Standard VT studies (ST VT).
In this series of experiments, lungs were ventilated with PIP ϭ 10 -12 cmH 2 O, an increase in ϳ30 -40% increase relative to Low VT experiments; the effect of Pla 2 and test reagents (heparanase III, Fig. 3 . Attenuation of lung mechanotransduction during Low VT. Effect of heparanase III (Hep; 150 mIU/ml), L-NAME (200 M), Mn(III)-tetra(4-benzoic acid) porphyrin chloride (TBAP; 200 M), and S-nitrosoglutathione (GSNO; 500 M) on Kfc2/Kfc1 when Pla ϭ 15 cmH2O. Baseline Kfc1 ratio (C7-7) is shown for comparison. Heparanase III and L-NAME significantly reduced the increase in Kfc2 when Pla ϭ 15 cmH2O. TBAP had no effect on pressure-induced increase in Kfc2/Kfc1. GSNO increased mean Kfc2/Kfc1 to 9.06ϩ3.26 vs. untreated lungs at Pla ϭ 15 cmH2O (P Ͻ 0.0001). Experiments were performed during Low VT ventilation; n ϭ 8 -9/group. Fig. 2 . Effect of Pla on Kfc2/Kfc1. Group numbers represent the 2 values of Pla at which Kfc1 and Kfc2 were derived. All groups had baseline Kfc (Kfc1) assessed at Pla ϭ 7 cmH2O. The second step in Pla was to 7, 10, 12, 15, or 17 cmH2O, corresponding to C7-7, C7-10, C7-12, C7-15, C7-17, respectively. The same group numbering system was used in nitro-L-arginine methyl ester (L-NAME)-treated lungs. A: in control lungs (C) during Low VT, baseline Kfc1 was measured at 7.5 cmH2O and Kfc2 was measured at 7.5, 10, 12, 15, or 17 cmH2O. The ratio of Kfc2/Kfc1 vs. Pla was constant at pressures over the range of 7.5 to 12 cmH2O. Kfc2/Kfc1 increased significantly when Pla2 ϭ 15 cmH2O and 17 cmH2O; n ϭ 8 -13/group. B: L-NAME (LN, 200 M) attenuated the increase in Kfc2/Kfc1 when Pla2 ϭ 15 and 17 cmH2O; n ϭ 6 -10/group. heparanase III ϩ DEPC, L-NAME, D-NAME, GSNO) on K fc were measured at Pla ϭ 7. Fig. 4 . Zonal characteristics (ZC) during increase in Pla. A: ZC was calculated at each Pla for control lungs and L-NAME-treated lungs at Low VT. ZC increased significantly between Pla ϭ 7.5 and 10 cmH2O but was not statistically changed when Pla Ͼ 12 cmH2O. L-NAME had no effect on ZC relative to controls at any given Pla. B: heparanase III (HepIII) and L-NAME had no effect on ZC at Pla ϭ 15 cmH2O relative to untreated lungs. ZC analysis suggests recruitment was not influencing the affects of treatments (heparanase and L-NAME) on Kfc during elevated vascular pressure. Open circles represent outliers. Fig. 5 . Interstitial volume after elevated Pla during Low VT. Retained lung weight after measurement of Kfc2 was used as a marker of interstitial volume (⌬VI) and normalized to the predicted lung weight (PLW). Heparanase III and L-NAME significantly reduced ⌬VI/PLW, consistent with a reduction in vascular permeability. B: at ST VT, increasing Pla2 to 15 cmH2O significantly increased the Kfc2/Kfc1 ratio compared with baseline (Pla ϭ 7.5 cmH2O). Heparanase III (Hep7-15) significantly reduced the Kfc2/Kfc1 ratio at Pla ϭ 15 cmH2O; inactive heparanase [Hep7-15 ϩ diethyl pyrocarbonate (DEPC)] had no effect on Kfc2. L-NAME reduced Kfc2 by almost 50% during ST VT and Pla ϭ 15 cmH2O, but the decrease did not reach statistical significance. GSNO significantly increased Kfc2 when Pla ϭ 15 cmH2O. C: increases in Pla to 17 cmH2O result in marked pulmonary edema that was significantly reduced by heparanase (Hep7-17) and L-NAME (LN7-17).
0.21 and K fc2 /K fc1 ϭ 3.12 Ϯ 1.93 (n ϭ 12) (Fig. 6B) . DEPC inhibits heparanase by binding to the histidine residue within the active site and renders the enzyme inactive (35a). This approach mitigates changes in enzyme structure that would be altered by boiling as a means of inactivation. Heparanase III was incubated with DEPC (100 nM; 20 min), then added to the circulating perfusate. In contrast to active enzyme, heparanase-DEPC had no effect on pressure-induced increase in K fc2 /K fc1 (Fig. 6B) .
When Pla was increased to 17 cmH 2 O, K fc2 /K fc1 increased to 15.8 from 4.08 (Fig. 6C) .
Heparanase III significantly attenuated the increase in K fc at Pla ϭ 17 cmH 2 O (P Ͻ 0.01) (Fig. 6C) .
L-NAME/D-NAME/GSNO. We tested the effect of L-NAME (200 M) and D-NAME (200 M) on K fc when Pla 2 ϭ 15 or 17 cmH 2 O. L-NAME significantly decreased K fc2 when Pla 2 ϭ 15 and 17 cmH 2 O (Fig. 6, B and C) . D-Name had no effect on K fc (data not shown). GSNO significantly increased K fc2 /K fc1 , from 7.1 to 11.0 when Pla 2 was increased to 15 cmH 2 O (P Ͻ 0.01, Fig. 6B ).
ZONAL CHARACTERISTICS. With ST VT, ZC was 0.68, 0.79 and 0.79 at Pla 2 ϭ 7.5, 15, and 17 cmH 2 O, respectively; heparanase III and L-NAME had no effect on ZC ( Fig. 7A and B) .
INTERSTITIAL MECHANICS. To assess the effect of increased Pla 2 and treatments (heparanase III, L-NAME) on interstitial mechanics, we measured the retained lung weight (⌬VI) after the second pressure step and normalized this value to PLW. Plots of ⌬VI/PLW closely parallel the relationship of K fc2 /K fc1 ratio between groups. There were no significant differences when Pla 2 ϭ 15 cmH 2 O between control, heparanase IIItreated, or L-NAME-treated lungs (Fig. 8A) . When Pla 2 ϭ 17 cmH 2 O, heparanase III and L-NAME significantly reduced ⌬VI/PLW (Fig. 8B) .
Protocol 3: single pressure step. To assess the effect of the baseline pressure step (Pla 1 ) on subsequent K fc measurements (i.e., priming effect), we performed a single step from isogravimetric pressure (0 -2 cmH 2 (Fig. 9) .
L-NAME lower K fc by 50%, compared with controls (in the single pressure step protocol. 0.13 Ϯ 0.09 vs. 0.33 Ϯ 0.16 ml·min Ϫ1 ·cmH 2 O Ϫ1 per 100 g; p ϭ 0.11) (Fig. 9) . In fact, K fc Fig. 7 . ZC after elevated Pla with ST VT. A: ZC was calculated at Pla ϭ 15 cmH2O for control lungs (C7-15), heparanase III-treated (Hep7-15), and L-NAME-treated lungs (LN7-15). There was no difference in ZC between groups. Baseline ZC at Pla ϭ 7.5 cmH2O (C7-7) is shown for comparison. B: ZC shown for controls (C7-7) and when Pla ϭ 17 cmH2O (C7-17); heparanase and L-NAME had no effect on ZC at Pla ϭ 17 cmH2O. ) and L-NAME (LN7-15) had no effect on ⌬VI/PLW compared with control lungs (C7-15). B: during ST VT and Pla ϭ 17 cmH2O, lung water increased significantly and was attenuated by both heparanase and L-NAME.
measured from L-NAME-treated lungs using the single pressure protocol at Pla ϭ 15 cmH 2 O, was reduced by almost 50% compared with the corresponding K fc2 from L-NAME-treated lungs during the double pressure pulse protocol (0.13 Ϯ 0.09 vs. 0.23 Ϯ 0.12, ml·min Ϫ1 ·cmH 2 O Ϫ1 per 100 g), respectively. IMMUNOHISTOCHEMISTRY. To validate the effects of heparanase III on removing lung HS, anti-HS antibody (HSS-1) was used to stain for HS. Control lungs demonstrate substantial capillary staining for HS within the alveolar septa (Fig. 10A) ; heparanase III completely abolished HS staining (Fig. 10B ). An alternative approach to validate the efficacy of heparanase III was achieved by using 3G10, an antibody that recognizes the neoepitope on the HS chain generated by the activity of heparanase III. Control lungs showed no 3G10 staining whereas heparanase III -treated lungs showed significant staining (Fig. 10, C and D) . Collectively, these two complementary approaches demonstrate significant removal of HS from the lung vasculature.
Staining for nitrotyrosine was increased in lungs exposed to increased vascular pressure (Pla 2 7.5 vs. 15 cmH 2 O) as shown in Fig. 11, A vs. B, respectively. During low vascular pressure (Pla 2 ϭ 7.5 cmH 2 O), small regions of positive staining are seen at low power (ϫ20) and shown as a close-up (inset, ϫ60) (Fig.  11A) . Following exposure to Pla 2 ϭ 15 cmH 2 O, an increase in nitrotyrosine staining is observed in both low-and highpowered images (Fig. 11B) . Heparanase-treatment before increasing vascular pressure significantly reduced nitrotyrosine staining (Fig. 11C) .
TISSUE NOX. We directly measured lung tissue NO x concentrations. The relationship between NO concentration vs. K fc2 / K fc1 for pooled Low VT and ST VT are presented in Fig. 12A . The Low VT group shows a statistically significant linear correlation between NOx vs. K fc2 /K fc1 (r 2 ϭ 0.59, n ϭ 29) and the Low VT group is left shifted compared with the ST VT group (inset). The combination of increased vascular pressure and ST VT resulted in significantly higher tissue NO x concentrations; the NO vs. K fc2 /K fc1 relationship was fitted to an exponential curve (r 2 ϭ 0.92); the permeability response was flat above an NO x concentration of ϳ4 mol.
Tissue NO x levels are presented in Fig. 12 , B and C. During Low VT and baseline Pla (7.5 cmH 2 O), tissue NO x was low (0.028 Ϯ 0.026 mol) and increased almost 12-fold when vascular pressure was increased to 15 cmH 2 O (C7-15; mean NO x ϭ 0.35 mol; P Ͻ 0.01). GSNO increased tissue NO x levels to 0.70 mol. Heparanase III treatment had no effect on NO x levels during baseline Pla (Hep7-7); during elevated vascular pressure, heparanase (Hep7-15) decreased the tissue NO x from 0.35 to 0.23 mol (P Ͼ 0.05). NO x could not be Fig. 9 . Pressure-conditioning: single pressure step protocol. Lungs exposed to a single increase in Pla from isogravimetric conditions to 15 cmH2O (C0 -15 cmH2O) had a Kfc significantly less than the Kfc derived from the double pressure step protocol at Pla2 ϭ 15 cmH2O. Heparanase III and L-NAME reduced the single-step Kfc by 20 -50%, but this reduction did not reach statistical significance. measured in the L-NAME groups because L-NAME liberates NO x , which interferes with the assay.
During ST VT, increasing vascular pressure resulted in an exponential increase in tissue NO x . Baseline NO x at Pla ϭ 7.5 cmH 2 O (C7-7) was 0.03 mol, which is identical to that of the Low VT group. However, the combination of higher VT and increasing in vascular pressure to 15 and 17 cmH 2 O resulted in marked increased NO x concentrations to 0.7 and 8.4 mol, respectively (Fig. 12C) . GSNO was synergistic with increasing Pla and increased NO x levels to 2.6 mol. Heparanase III significantly attenuated the increase in NO x when Pla ϭ 15 cmH 2 O to 0.5 mol (P Ͻ 0.01, Fig. 12C ).
DISCUSSION
The major findings of this study were 1) K fc increased in a nonlinear relationship to vascular pressure, over the range of 7.5 to 17 cmH 2 O; 2) heparanase III significantly attenu- Fig. 11 . Immunohistochemistry for nitrotyrosine. A: control lungs at Pla ϭ 7.5 cmH2O showed patchy staining. B: when lungs were exposed to Pla ϭ 15 cmH2O, marked nitrotyrosine staining was evident. C: heparanase III treatment prior to increasing Pla attenuated nitrotyrosine staining. NOx levels when Pla ϭ 15 cmH2O. Heparanase treatment at low Pla had no effect on NOx (Hep7-7) but significantly reduced NOx concentrations at Pla ϭ 15 cmH2O, (Hep7-15). C: during ST VT increases in Pla to 15 cmH2O result in large increases in NOx to 0.70; GSNO at Pla ϭ 15 cmH2O further increased NOx to 2.60. When Pla ϭ 17 cmH2O, NOx increased to 8.41; heparanase significantly reduced the NOx to 0.54, when Pla ϭ 15 cmH2O (n ϭ 4 -6). m1-m4, fit parameters. Chisq, chi squared. ated the pressure-induced increase in K fc2 and inactivation of heparanase III by DEPC abolished its inhibitory effect; 3) L-NAME (200 M) significantly attenuated the pressureinduced increase in K fc2 , whereas the NO donor GSNO increased permeability; 4) TBAP had no effect on pressureinduced increase in K fc2 ; and, finally, 5) the first step increase in Pla increased the sensitivity of the vasculature to the second step in Pla, a phenomenon we call pressure conditioning.
Nonlinear Relationship of K fc vs. Pla
For our initial studies, we performed a detailed characterization of increasing Pla on K fc . In these studies, K fc1 was measured in all lungs at Pla 1 ϭ 7.5 cmH 2 O. After a second isogravimetric period, Pla 2 was increased to 7.5, 10, 12, 15, or 17 cmH 2 O and K fc2 was derived. In each set of experiments, the ratio of K fc2 /K fc1 was calculated to establish the influence of Pla 2 on whole lung permeability; the K fc2 /K fc1 ratio did not significantly change until Pla 2 ϭ 15 cmH 2 O. The K fc2 /K fc1 ratio following double pressure steps of 7.5/7.5, 7.5/10, 7.5/12, 7.5/15, and 7.5/17 was 1.43, 1.43, 2.83, 7.5, and 9.86, respectively. The nonlinear dynamics of the pressure vs. permeability relationship mimics what was observed in a cell culture model using lung capillary endothelial cells (15) and suggests a non-Starling mechanism. K fc is the transvascular water flux normalized to capillary pressure and, therefore, assuming vascular permeability remained unaltered by pressure, the K fc vs. Pla relationship should have a slope of zero. The nonlinear relationship, which has been reported in vitro, and now in a whole organ model, suggests a non-Starling mechanism consistent with active vascular mechanotransduction.
L-NAME had no effect on baseline K fc1 but significantly attenuated the increase in K fc2 when Pla 2 ϭ 15 and 17 cmH 2 O. These findings are similar to results obtained from monolayers of bovine lung capillary endothelial cells (15, 19, 43) . The increase in hydrostatic pressure appears to activate eNOS, leading to an increase in endothelial permeability. The role of hydrostatic pressure and increased transendothelial flow on NO production has been reported by Burns et al. (12) , using human umbilical vein endothelial cells as a model system. Thus there is a consistent finding both in vitro and now in an ex vivo lung preparation where pressure-mediated mechanotransduction involves eNOS activation and subsequent barrier dysfunction. GSNO, an NO donor, exacerbated pressure induced increase in K fc during both Low VT and ST VT protocols, supporting the conclusion that NO is a mediator of lung endothelial barrier dysfunction.
Heparanase Experiments
This is the first study to demonstrate a role for vascular HS on mechanotransduction using a whole lung model. In the present study, heparanase III (E.C. 4.2.2.8) had no effect on baseline K fc1 yet significantly attenuated the increase in K fc2 when Pla 2 was increased to 15 and 17 cmH 2 O (Figs. 3 and 6) . These results are similar to our observations in vitro (15) strongly supporting the conclusion of glycocalyx-mediated mechanotransduction (26, 36, 42) . We tested DEPC-inactivated heparanase III and found that it had no effect on reducing K fc , during elevated vascular pressure; thus heparanase's enzymatic activity was required to attenuate mechanotransduction. To validate the removed of HS by heparanase, we performed immunohistochemistry and demonstrated nearly complete removal of vascular heparan staining after heparanase treatment. Likewise, the staining of heparanase-treated lungs by 3G10, an antibody that recognizes the neoepitope created by heparanase, demonstrated robust staining.
To determine whether heparanase's reduction in K fc was actually due to a reduction in permeability and not due to altered interstitial pressure, we present the following line of reasoning. Negrini et al. (28) used intravascular heparanase III to induce lung injury in rabbits and reported an increase in interstitial pressure due to the accumulation of interstitial fluid.
In their experiments, heparanase III-treated lungs had an increase in wet-to-dry weight ratio consistent with an increase in interstitial fluid. As interstitial pressure increased, the gradient for fluid flux decreased and, therefore, could reduce the apparent value of K fc . In the present study, the increase in lung weight following each pressure step was taken as a marker for ⌬VI (45); heparanase III-treated lungs had a significantly lower ⌬VI/PLW at Pla ϭ 15 and 17 cmH 2 O compared with controls (Figs. 5 and 8), consistent with a reduction in endothelial permeability and reduced interstitial edema. The significantly lower values for both K fc and ⌬VI/PLW in heparanase-treated lungs support the conclusion that mechanotransduction and increased permeability were attenuated by removal of vascular HS.
TBAP
TBAP is a cell-permeable superoxide dismutase mimetic that scavenges free radicals. We previously reported (15) that TBAP attenuated pressure-induced increases in endothelial permeability, suggesting that ROS were partially involved in barrier alterations. In the present study, TBAP had no effect on pressure-induced increase in K fc . We conclude that ROS are not the cause of pressure-mediated barrier dysfunction in this ex vivo lung model.
Technical Considerations
The relationship between Pla, Ppc, and K fc is complex and requires assumptions that have been addressed elsewhere (9) . To rule out factors other than mechanotransduction that could have influenced measured K fc , we address the following technical issues.
Pulmonary hemodynamics. Ppa, pulmonary artery flow, and Pdo 1 , Pdo 2 , and Pdo 3 were measured throughout the experiment. There were no significant differences in pulmonary hemodynamic variable that could explain the observed differences in K fc2 when Pla 2 ϭ 15 or 17 cmH 2 O (Table 1) .
Recruitment. Fluid flux is dependent on vascular surface area; if step increases in Pla increased recruitment, our measured K fc values may reflect only the increasing surface area and not an actual change in endothelial permeability. Short et al. (40) reported that, in rat lungs, recruitment of subpleural capillaries accurately reflected recruitment of interior capillaries; using similar methods, Presson et al. (35) showed that lung capillary recruitment was 90% complete when capillary pressure equaled 10 cmH 2 O and was nearly 100% complete when capillary pressure was 12 cmH 2 O. Pulmonary artery pressure is an indicator of downstream resistance and should decrease with increasing vascular recruitment. In the present study Ppa was stable after 3-5 min following the step increase in Pla, suggesting that recruitment and downstream resistance was not changing.
Evaluation of ZC (ϭ ⌬Ppa/⌬Pla) was undertaken to further evaluate the effects of increased Pla on vascular recruitment and to quantify the relative degree of Zone 2 and Zone 3 conditions throughout the experiments. During Low VT experiments when Pla 2 ϭ 7.5 cmH 2 O, all lungs were primarily in Zone 2 as evidenced by ZC ϭ 0.44. Increases in Pla 2 to 10, 12, 15, and 17 cmH 2 O increased ZC to 0.58, 0.64, 0.71, and 0.76, respectively. According to ZC analysis, recruitment was completed when Pla ϭ 12 cmH 2 O consistent with the finding of Presson et al. (35) . In summary, K fc continued to increase after ZC had plateaued, suggesting that changes in endothelial permeability as the cause for increased K fc .
Mechanism of Pressure-Induced Increase in K fc
Our results, using an intact lung model, demonstrate that permeability changes as a function of vascular pressure and are similar to mechanotransduction pathways elucidated with use of cultured endothelial cells (12, 15, 16, 18, 31) . These findings challenge the Starling principle and demonstrate non-Starling mechanism(s) to account for the development of pulmonary edema. Enhanced staining of NO-tyrosine during increased vascular pressure and the reduction of NO-tyrosine after heparanase treatment strongly supports our hypothesis for a HSeNOS mechanotransduction pathway. In fact, direct measurement of tissue NO x showed increasing tissue NO x with increased vascular pressure. Heparanase III reduced tissue NO x concentration by 50% when Pla ϭ 15 cmH 2 O in the Low VT groups and reduced NO x by eightfold, when Pla ϭ 17 cmH 2 O, during ST VT. Lastly, GSNO increased tissue NO x and significantly increased K fc during elevated vascular pressure. Taken together, these results support our conclusion that NO x is involved in barrier dysfunction. A schematic for the proposed mechanism of glycocalyx mechanotransduction is shown in Fig. 13 .
Kuebler (24) has shown that an increase in Pla increases lung capillary NO formation, consistent with the findings of our study. In fact, high vascular pressure has been shown to activate cytochrome P-450 (CYP450)-dependent pathways in the lung resulting in increased K fc and metabolites of the CYP450 pathway, including 20-HETE, can activate eNOS in pulmonary endothelial cells (13) . Experiments to elucidate the mechanism(s) linking the glycocalyx to eNOS activation and alterations in barrier function are currently underway in our laboratory. Stretch-activated transient receptor potential (TRP) channels likely participate in lung vascular mechanotransduction and have been shown to modulate both CYP450 pathways and eNOS activation (5, 21, 44) .
Airway Pressures and K fc
A major finding of the present study was the combined influence of airway pressure and VT on tissue NO x and K fc when vascular pressure was increased. At ST V T , baseline K fc was not different than baseline K fc at Low VT (Fig. 6A) , thus endothelial permeability is not altered by the changes in VT when Pla Ͻ 15 cmH 2 O. When lungs were ventilated with ST VT and Pla was elevated, K fc increased to a greater extent than when lungs were ventilated with Low VT at elevated Pla. For example, at Low VT and Pla ϭ 17 cmH 2 O, K fc2 increased ϳ5-fold (Fig. 2) whereas at ST VT and Pla ϭ 17 cmH 2 O, K fc2 increased ϳ15-fold. Thus inflation pressure had a significant effect on the permeability response to increased vascular pressure.
Heparanase and L-NAME had a greater effect in the reduction of K fc during ST VT compared with Low VT. These results cannot be explained by changes in vascular recruitment, since ZC did not change with heparanase or L-NAME treatments.
Yin et al. (47) demonstrated that in statically inflated lungs NO participates in a negative feedback loop, via a cGMP mechanism, that attenuates hydrostatic pulmonary edema. They suggest that elevated vascular pressure activates stretchinduced calcium channel opening (presumably TRPV4) resulting in eNOS activation, NO-stimulated soluble guanylate cyclase activity, and cGMP-mediated inactivation of TRPV4 channels. In their model, L-NAME exacerbated pressure-induced K fc and NO donors attenuated pressure-induced increase in K fc . The major difference that explains the results of Yin et al. Compared with the present work is the role of cyclic ventilation in maintaining endothelial cGMP levels. Lung cGMP levels are positively influenced by mechanical ventilation and nonventilated lungs show a significant reduction in cGMP levels (8, 22, 34) . A complex interplay between endothelial cell cGMP concentrations and barrier function has recently been described by Pearse and colleagues (34, 37) and Kuebler (23) , who demonstrated that cGMP concentrations increased in lung endothelial cells in a VT-and time-dependent manner. This increase in cGMP stimulates the activity of PDE2A, an enzyme that degrades cyclic AMP, leading to barrier dysfunction and elevated K fc . Support for this idea can be inferred from the findings of Parker and Ivey (32) , who reported that high vascular pressure-induced permeability was attenuated with isoproterenol, a ␣-adrenergic agonist that increases intracellular cAMP.
Direct measurements of tissue NO x in lung samples from our study revealed differences in the NO x concentrations vs. K fc2 / K fc1 relationship (Fig. 12) depending on VT; the slope of NO x vs. K fc2 /K fc1 was steeper and left shifted in the Low VT group compared with the ST VT group. This means that during low VT, vascular permeability was greater at a given NO x concentration. During ST VT there is a large increase in tissue NO x in response to elevated vascular pressure; this supports our conclusion that the combined effects of alveolar stretch and endothelial mechanotransduction result in more severe edema development.
NO can contribute to barrier dysfunction through mechanisms other than altering cGMP-to-cAMP ratios. For example, NO and its reactive metabolites such as peroxynitrite can directly nitrosylate tyrosine residues on endothelial proteins, resulting in barrier dysfunction. NO
• and ONOO • -induced nitrosylation of ␤-actin are principal mechanisms of TNFinduced barrier dysfunction (29) . Our immunohistochemistry data demonstrated an increase in NO-tyrosine staining in lungs subjected to increased Pla and, conversely, a reduction in NO-tyrosine in heparanase-treated lungs. Superoxide anions, produced via the activation of NAD(P)H oxidase (17) and mitochondrial oxidases (4, 39), can react with endogenous NO to generate peroxynitrites, leading to oxidative barrier dysfunction. The lack of effect of TBAP, an intracellular superoxide dismutase mimetic, suggests that ROS are not the primary mechanism underlying pressure-induced increase in K fc .
NO can also nitrosylate and activate conductance of the TRPfamily ion channels that allow calcium influx and sustain the calcium-dependent activation of eNOS (48) . Cytoplasmic cys553 and cys558 can be S-nitrosylated and appear to account for the direct NO sensitivity of TRPC5, TRPV1, TRPV3, and TRPV4 channel gating. Other TRP family members including TRPC1 and TRPC4 possess conserved cys residues on the putative pore region that predicts NO-sensitive activation. The balance between cGMP gating of stretch activated channels as proposed by Yin et al. (47) and NO activation of TRP channel (48) has yet to be reconciled in the lung vasculature. Nitrosylation of TRP channels and subsequent calcium influx may lead to continued activation of eNOS and resultant barrier dysfunction.
Clinical Relevance
The Acute Respiratory Distress Syndrome Network data has demonstrated that low-VT ventilation improves outcomes in patients with existing lung injury (1, 6), whereas conservative fluid strategies improve pulmonary function and reduce ventilator-free days (46) . From a clinical perspective, lung vascular mechanotransduction may contribute to worsening extravascular lung water resulting from overaggressive fluid resuscitation in combination with elevated airway pressure and may help explain the beneficial mechanism(s) of conservative fluid management and low-VT ventilation.
